Literature DB >> 26609042

First confirmed case of Crimean-Congo haemorrhagic fever from Sirohi district in Rajasthan State, India.

Darshana Makwana, Pragya D Yadav, Arjun Kelaiya, Devendra T Mourya1.   

Abstract

Entities:  

Mesh:

Year:  2015        PMID: 26609042      PMCID: PMC4683835          DOI: 10.4103/0971-5916.169221

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


× No keyword cloud information.
Sir, Crimean-Congo haemorrhagic fever (CCHF) is a tick-borne viral disease with average mortality rate of 30-50 per cent1. In India, presence of CCHF was first time confirmed in Gujarat State during a nosocomial outbreak in 201123. Since then, numerous outbreaks and sporadic cases of this disease have been reported from different districts of Gujarat State456. Studies conducted at the National Institute of Virology (NIV), Pune, had reported the presence of anti-CCHF IgG antibodies in domestic animals from Sirohi district, Rajasthan State. However, in the last four years none of the referred human samples were found positive3456. On March 18, 2014, blood sample of a suspected CCHF case was referred to NIV, Pune, for aetiology confirmation. This suspected CCHF case was a 45 yr old male, shepherd by profession, residing at Veravilapur village, Sirohi district, Rajasthan. He was presented on March 14, 2014, with complains of abdominal discomfort since last six days and vomiting since one day along with history of intermittent fever since 15 days. He had moderate fever without chills and was associated with arthralgia, generalized body ache, constipation, decreased urine output, bleeding from nose, haematuria and bleeding per rectum. He was a known case of HBsAg reactivity, and was transferred from Rajasthan State to Civil hospital, Ahmadabad, Gujarat. On admission, patient had thrombocytopenia (20,000/μl). Serum creatinine was 1.2 mg/dl, prothrombin time 15.3 sec, International Normalized Ratio (INR) 1.15, and activated partial thromboplastin time (APTT) was 50.0 sec (Table). There was impairment of liver function test in the form of markedly elevated liver enzymes of serum glutamic-pyruvic transaminase (SGPT: 2620 U/l) with normal serum total bilirubin (0.40 mg/dl) and normal renal function. Parameters of complete blood count were in the normal range (Table).
Table

Day-wise clinical laboratory findings of Crimean-Congo haemorrhagic fever (CCHF) case in 2014

Day-wise clinical laboratory findings of Crimean-Congo haemorrhagic fever (CCHF) case in 2014 The differential diagnosis of CCHF at the pre-haemorrhagic stage is more difficult. As the disease progresses, clinical features become clearer and diagnosis becomes easier. The sample was differentially tested for some aetiological agents (hepatitis viruses, Leptospira and dengue viruses) which are endemic in the region and mimic the clinical illness of CCHF. Apart from HBsAg, patient was negative for viral markers (i.e. anti-HEV IgM, anti-HAV IgM, anti-HCV IgM). Anti-HIV antibodies, anti-Leptospira IgM and IgG antibodies, dengue IgM antibody, blood and urine culture were negative. The patient did not have any recent travel history to Gujarat State; but had close contact with livestock. Whole blood of the patient was collected on March 15, 2014 (2nd day of admission) and March 19, 2014 (6th day of admission). On day 19, urine sample was also collected. The patient's serum and urine samples were processed for CCHF virus specific real-time RT-PCR57. Anti-CCHF IgM antibodies were tested in serum samples using commercial CCHF IgM ELISA Kit (Vector-Best, Novosibirsk, Russia). Real-time RT-PCR results were found positive for both serum samples collected on day 15th [threshold cycle (Ct) =27] and on 19th day (Ct=34)]. On 19th day urine sample showed Ct=38. Both serum samples (of 15th and 19th days) were positive for IgM antibodies against CCHF virus. Real-time reverse-transcription RT-PCR data showed high CCHF viral copy number. On 19th post illness day, the urine sample also showed low level of CCHF viral RNA. As soon as the sample was laboratory confirmed as CCHF case, the patient was put in strict isolation. For treatment, oral ribavirin was administered on day 3 after admission on clinical suspicion at the dosage recommended by the World Health Organization8910, along with the supportive and replacement therapy with blood products. The patient responded to the treatment and recovered completely, and was discharged on request on March 27, 2014 (14th day of admission). Livestock trade and movements of domestic animals infested with infected ticks might be the reason in distribution of infected ticks to newer areas, and eventually spread of CCHFV. As CCHF mimics a wide range of common illnesses caused by different aetiological agents which are endemic in India, differential diagnosis should be done based on clinical biochemical, haematological, bacteriological and virological findings. These include Kyasanur forest disease, hepatitis, Neisseria meningitidis infection, leptospirosis, borreliosis, typhoid, rickettsiosis, dengue and malaria. However, malaria diagnosis can be excluded in cases of suspected viral haemorrhagic fever (VHF)11. In conclusion, there is a need to initiate active serosurvey of CCHF among human population, and domestic animals in Rajasthan. This will be helpful in understanding the prevalence of this disease in Rajasthan State which eventually will alert the State health authorities.
  8 in total

Review 1.  The epidemiology of tick-borne Crimean-Congo hemorrhagic fever in Asia, Europe, and Africa.

Authors:  H Hoogstraal
Journal:  J Med Entomol       Date:  1979-05-22       Impact factor: 2.278

2.  Emergence of Crimean-Congo hemorrhagic fever in Amreli District of Gujarat State, India, June to July 2013.

Authors:  Pragya D Yadav; Yogesh K Gurav; Madhulika Mistry; Anita M Shete; Prasad Sarkale; Avinash R Deoshatwar; Vishwa B Unadkat; Prasad Kokate; Deepak Y Patil; Dinkar K Raval; Devendra T Mourya
Journal:  Int J Infect Dis       Date:  2013-11-07       Impact factor: 3.623

3.  Effect of oral ribavirin treatment on the viral load and disease progression in Crimean-Congo hemorrhagic fever.

Authors:  Hürrem Bodur; Ayşe Erbay; Esragül Akıncı; Pınar Öngürü; Nurhayat Bayazıt; Selim Sırrı Eren; Ayhan Kubar
Journal:  Int J Infect Dis       Date:  2010-11-23       Impact factor: 3.623

4.  Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR.

Authors:  Christian Drosten; Stephan Göttig; Stefan Schilling; Marcel Asper; Marcus Panning; Herbert Schmitz; Stephan Günther
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

5.  The efficacy of oral ribavirin in the treatment of crimean-congo hemorrhagic fever in Iran.

Authors:  M Mardani; M Keshtkar Jahromi; K Holakouie Naieni; M Zeinali
Journal:  Clin Infect Dis       Date:  2003-06-04       Impact factor: 9.079

6.  Detection, isolation and confirmation of Crimean-Congo hemorrhagic fever virus in human, ticks and animals in Ahmadabad, India, 2010-2011.

Authors:  Devendra T Mourya; Pragya D Yadav; Anita M Shete; Yogesh K Gurav; Chandrashekhar G Raut; Ramesh S Jadi; Shailesh D Pawar; Stuart T Nichol; Akhilesh C Mishra
Journal:  PLoS Negl Trop Dis       Date:  2012-05-15

7.  Re-occurrence of Crimean-Congo haemorrhagic fever in Ahmedabad, Gujarat, India (2012): a fatal case report.

Authors:  Pragya D Yadav; Chandrashekhar G Raut; Devendra T Mourya
Journal:  Indian J Med Res       Date:  2013-12       Impact factor: 2.375

Review 8.  Crimean-Congo haemorrhagic fever.

Authors:  Onder Ergönül
Journal:  Lancet Infect Dis       Date:  2006-04       Impact factor: 25.071

  8 in total
  7 in total

Review 1.  An Emerging Biothreat: Crimean-Congo Hemorrhagic Fever Virus in Southern and Western Asia.

Authors:  Paul W Blair; Jens H Kuhn; David B Pecor; Dmitry A Apanaskevich; Mark G Kortepeter; Anthony P Cardile; Aileen Polanco Ramos; Maryam Keshtkar-Jahromi
Journal:  Am J Trop Med Hyg       Date:  2019-01       Impact factor: 2.345

2.  Second International Conference on Crimean-Congo Hemorrhagic Fever.

Authors:  Jessica R Spengler; Dennis A Bente; Mike Bray; Felicity Burt; Roger Hewson; Gülay Korukluoglu; Ali Mirazimi; Friedemann Weber; Anna Papa
Journal:  Antiviral Res       Date:  2017-12-02       Impact factor: 5.970

3.  Nosocomial infection of CCHF among health care workers in Rajasthan, India.

Authors:  Pragya D Yadav; Deepak Y Patil; Anita M Shete; Prasad Kokate; Pulkit Goyal; Santosh Jadhav; Sanjeev Sinha; Divya Zawar; Surendra K Sharma; Arti Kapil; D K Sharma; Kamlesh J Upadhyay; Devendra T Mourya
Journal:  BMC Infect Dis       Date:  2016-11-03       Impact factor: 3.090

Review 4.  Ribavirin for treating Crimean Congo haemorrhagic fever.

Authors:  Samuel Johnson; Nicholas Henschke; Nicola Maayan; Inga Mills; Brian S Buckley; Artemisia Kakourou; Rachel Marshall
Journal:  Cochrane Database Syst Rev       Date:  2018-06-05

5.  Retrospective analysis of clinical information in Crimean-Congo haemorrhagic fever patients: 2014-2015, India.

Authors:  Devendra T Mourya; Rajlakshmi Viswanathan; Santosh Kumar Jadhav; Pragya D Yadav; Atanu Basu; Mandeep S Chadha
Journal:  Indian J Med Res       Date:  2017-05       Impact factor: 2.375

Review 6.  A mini-review of Bunyaviruses recorded in India.

Authors:  Pragya D Yadav; Gouri Y Chaubal; Anita M Shete; Devendra T Mourya
Journal:  Indian J Med Res       Date:  2017-05       Impact factor: 2.375

7.  Crimean-Congo Hemorrhagic Fever in Migrant Worker Returning from Oman to India, 2016.

Authors:  Pragya D Yadav; Sachin Thacker; Deepak Y Patil; Rajlaxmi Jain; Devendra T Mourya
Journal:  Emerg Infect Dis       Date:  2017-06       Impact factor: 6.883

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.